Although sodium-glucose cotransporter 2 inhibitors (SGLT2is) were initially developed and approved by the US Food and Drug Administration (FDA) for the glycemic management of type 2 diabetes mellitus (DM2), their effect on cardiac and renal health has led to an expanded use in clinical practice. Here, SLC5A2 is linked to type 2 diabetes mellitus.